{"id":"transmucosal-buprenorphine","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Sweating"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine acts as a partial agonist at the mu-opioid receptor, meaning it produces submaximal effects compared to full agonists like morphine. This partial agonism provides analgesia and reduces withdrawal symptoms in opioid-dependent patients while having a built-in safety ceiling that limits respiratory depression risk. The transmucosal formulation allows absorption through oral mucosa, providing rapid onset suitable for maintenance treatment and acute pain management.","oneSentence":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:52.870Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder maintenance treatment"},{"name":"Acute pain management"},{"name":"Chronic pain"}]},"trialDetails":[{"nctId":"NCT07420283","phase":"PHASE2","title":"A Study of Brenipatide in Participants With Opioid Use Disorder","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-13","conditions":"Opioid Use Disorder","enrollment":465},{"nctId":"NCT04995029","phase":"PHASE4","title":"Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2021-10-26","conditions":"Moderate to Severe Opioid-use Disorder","enrollment":785},{"nctId":"NCT04600414","phase":"NA","title":"Collaborating to Heal Addiction and Mental Health in Primary Care","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-16","conditions":"Opioid-use Disorder, Mental Health Disorder","enrollment":254},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT03993392","phase":"PHASE4","title":"SUBLOCADE Rapid Initiation Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-08-29","conditions":"Opioid-use Disorder","enrollment":26},{"nctId":"NCT01666119","phase":"PHASE2","title":"An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects","status":"COMPLETED","sponsor":"BioDelivery Sciences International","startDate":"2012-08","conditions":"Opioid Dependence","enrollment":249},{"nctId":"NCT01946555","phase":"","title":"Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2013-09","conditions":"Tumor, Cancer Pain, Breakthrough Cancer Pain","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Transmucosal Buprenorphine","genericName":"Transmucosal Buprenorphine","companyName":"Indivior Inc.","companyId":"indivior-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial mu-opioid receptor agonist that binds with high affinity to reduce opioid cravings and withdrawal symptoms while producing a ceiling effect on respiratory depression. Used for Opioid use disorder maintenance treatment, Acute pain management, Chronic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}